Barclays downgraded shares of GlaxoSmithKline (LON:GSK) to an equal weight rating in a report published on Wednesday morning.

A number of other analysts have also issued reports on GSK. Kepler Capital Markets reaffirmed a hold rating on shares of GlaxoSmithKline in a research note on Tuesday. Liberum Capital reaffirmed a hold rating on shares of GlaxoSmithKline in a research note on Tuesday. Deutsche Bank reaffirmed a hold rating and issued a GBX 1,525 ($19.93) price target on shares of GlaxoSmithKline in a research note on Tuesday. Credit Suisse Group set a GBX 1,600 ($20.91) price objective on GlaxoSmithKline and gave the stock a neutral rating in a research note on Tuesday. Finally, UBS Group reissued a buy rating and set a GBX 1,700 ($22.21) price objective on shares of GlaxoSmithKline in a research note on Tuesday. One research analyst has rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the stock. The company currently has an average rating of Hold and a consensus target price of GBX 1,512.99 ($19.77).

Shares of LON:GSK opened at GBX 1,437.40 ($18.78) on Wednesday. GlaxoSmithKline has a 1 year low of GBX 1,235.20 ($16.14) and a 1 year high of GBX 1,724.50 ($22.53).

The business also recently disclosed a dividend, which will be paid on Thursday, January 10th. Shareholders of record on Thursday, November 15th will be paid a dividend of GBX 19 ($0.25) per share. This represents a yield of 1.26%. The ex-dividend date is Thursday, November 15th.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Recommended Story: Book Value Per Share in Stock Trading

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.